Takeda Pharmaceutical Statistics
Total Valuation
Takeda Pharmaceutical has a market cap or net worth of $44.74 billion. The enterprise value is $77.78 billion.
Important Dates
The last earnings date was Thursday, January 30, 2025, before market open.
| Earnings Date | Jan 30, 2025 |
| Ex-Dividend Date | Sep 30, 2024 |
Share Statistics
Takeda Pharmaceutical has 1.59 billion shares outstanding. The number of shares has increased by 1.17% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.59B |
| Shares Change (YoY) | +1.17% |
| Shares Change (QoQ) | -1.52% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.58B |
Valuation Ratios
The trailing PE ratio is 33.80.
| PE Ratio | 33.80 |
| Forward PE | n/a |
| PS Ratio | 1.54 |
| Forward PS | 0.02 |
| PB Ratio | 0.95 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 7.28 |
| P/OCF Ratio | 6.32 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 9.67, with an EV/FCF ratio of 12.66.
| EV / Earnings | 58.77 |
| EV / Sales | 2.67 |
| EV / EBITDA | 9.67 |
| EV / EBIT | 20.74 |
| EV / FCF | 12.66 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.31 |
| Quick Ratio | 0.59 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | 4.13 |
| Debt / FCF | 5.62 |
| Interest Coverage | 6.57 |
Financial Efficiency
Return on equity (ROE) is 2.94% and return on invested capital (ROIC) is 2.97%.
| Return on Equity (ROE) | 2.94% |
| Return on Assets (ROA) | 2.51% |
| Return on Invested Capital (ROIC) | 2.97% |
| Return on Capital Employed (ROCE) | 4.53% |
| Revenue Per Employee | $590,997 |
| Profits Per Employee | $26,854 |
| Employee Count | 49,281 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.31 |
Taxes
In the past 12 months, Takeda Pharmaceutical has paid $169.28 million in taxes.
| Income Tax | 169.28M |
| Effective Tax Rate | 11.33% |
Stock Price Statistics
The stock price has decreased by -5.13% in the last 52 weeks. The beta is 0.46, so Takeda Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -5.13% |
| 50-Day Moving Average | 13.32 |
| 200-Day Moving Average | 13.70 |
| Relative Strength Index (RSI) | 64.07 |
| Average Volume (20 Days) | 1,779,751 |
Short Selling Information
| Short Interest | 3.74M |
| Short Previous Month | 4.91M |
| Short % of Shares Out | 0.24% |
| Short % of Float | 0.24% |
| Short Ratio (days to cover) | 1.81 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of $29.12 billion and earned $1.32 billion in profits. Earnings per share was $0.83.
| Revenue | 29.12B |
| Gross Profit | 19.04B |
| Operating Income | 3.75B |
| Pretax Income | 366.81M |
| Net Income | 1.32B |
| EBITDA | 8.04B |
| EBIT | 3.75B |
| Earnings Per Share (EPS) | $0.83 |
Full Income StatementBalance Sheet
The company has $3.14 billion in cash and $34.55 billion in debt, giving a net cash position of -$31.40 billion or -$19.81 per share.
| Cash & Cash Equivalents | 3.14B |
| Total Debt | 34.55B |
| Net Cash | -31.40B |
| Net Cash Per Share | -$19.81 |
| Equity (Book Value) | 47.19B |
| Book Value Per Share | 29.77 |
| Working Capital | 4.17B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $7.08 billion and capital expenditures -$1.25 billion, giving a free cash flow of $6.15 billion.
| Operating Cash Flow | 7.08B |
| Capital Expenditures | -1.25B |
| Free Cash Flow | 6.15B |
| FCF Per Share | $3.88 |
Full Cash Flow StatementMargins
Gross margin is 65.38%, with operating and profit margins of 12.88% and 4.54%.
| Gross Margin | 65.38% |
| Operating Margin | 12.88% |
| Pretax Margin | 5.13% |
| Profit Margin | 4.54% |
| EBITDA Margin | 27.62% |
| EBIT Margin | 12.88% |
| FCF Margin | 21.10% |